Stock Scorecard
Stock Summary for Avidity Biosciences Inc (RNA) - $25.14 as of 4/24/2024 2:56:04 PM EST
Total Score
7 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RNA
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RNA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RNA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for RNA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for RNA
Financial Details for RNA
Company Overview |
|
|---|---|
| Ticker | RNA |
| Company Name | Avidity Biosciences Inc |
| Country | USA |
| Description | Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/7/2024 |
Stock Price History |
|
| Last Day Price | 25.14 |
| Last Day Price Updated | 4/24/2024 2:56:04 PM EST |
| Last Day Volume | 859,072 |
| Average Daily Volume | 1,169,755 |
| 52-Week High | 27.66 |
| 52-Week Low | 4.83 |
| Last Price to 52 Week Low | 420.50% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 100.27 |
| Sector PE | 60.54 |
| 5-Year Average PE | -5.42 |
| Free Cash Flow Ratio | 3.37 |
| Industry Free Cash Flow Ratio | 12.60 |
| Sector Free Cash Flow Ratio | 30.19 |
| Current Ratio Most Recent Quarter | 7.58 |
| Total Cash Per Share | 7.47 |
| Book Value Per Share Most Recent Quarter | 6.32 |
| Price to Book Ratio | 3.84 |
| Industry Price to Book Ratio | 5.66 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 200.88 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
| Total Shares Outstanding | 79,720,000 |
| Market Capitalization | 2,004,160,800 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -21.97% |
| Reported EPS 12 Trailing Months | -2.91 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -2.90 |
| Net Income Twelve Trailing Months | -212,220,000 |
| Net Income Past Year | -212,220,000 |
| Net Income Prior Year | -173,995,000 |
| Quarterly Revenue Growth YOY | -20.80% |
| 5-Year Revenue Growth | 13.27% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 595,400,000 |
| Total Cash Past Year | 595,400,000 |
| Total Cash Prior Year | 610,700,000 |
| Net Cash Position Most Recent Quarter | 595,400,000 |
| Net Cash Position Past Year | 595,400,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 4,544,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 500,764,000 |
| Total Stockholder Equity Prior Year | 578,075,000 |
| Total Stockholder Equity Most Recent Quarter | 500,764,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.91 |
| MACD Signal | 1.42 |
| 20-Day Bollinger Lower Band | 3.07 |
| 20-Day Bollinger Middle Band | 15.89 |
| 20-Day Bollinger Upper Band | 28.71 |
| Beta | 0.77 |
| RSI | 50.89 |
| 50-Day SMA | 11.25 |
| 200-Day SMA | 19.09 |
System |
|
| Modified | 4/23/2024 10:26:05 AM EST |